JMP Securities analyst Reni Benjamin downgraded Spectrum Pharmaceuticals (SPPI) to Market Perform from Outperform without a price target following the proposed acquisition by Assertio Holdings (ASRT). Given the acquisition price and the current state of the capital markets, the analyst does not expect any other bidders. The stock should trade closer to the upfront consideration of $1.14 as the completion of the acquisition gets closer, making the shares fairly valued, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SPPI:
- Spectrum Pharma Skyrockets on Acquisition by Assertio
- Assertio to acquire Spectrum in all-stocl and CVR transaction
- Spectrum to participate in a conference call with JMP Securities
- Spectrum reports Q4 EPS (5c), consensus (11c)
- Spectrum options imply 25.8% move in share price post-earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue